Celsion Corp CLSN
We take great care to ensure that the data presented and summarized in this overview for Celsion CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CLSN
Top Purchases
Top Sells
About CLSN
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Insider Transactions at CLSN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2024
|
Michael H Tardugno Executive Chairman of Board |
BUY
Open market or private purchase
|
Direct |
25,000
+6.61%
|
$25,000
$1.03 P/Share
|
|
Aug 15
2024
|
Stacy Lindborg President and CEO |
BUY
Open market or private purchase
|
Direct |
25,000
+8.65%
|
$0
$0.98 P/Share
|
|
Dec 07
2023
|
Sebastien Hazard Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Jul 18
2022
|
Corinne Le Goff President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
53,000
+50.0%
|
-
|
|
Apr 12
2022
|
Michael H Tardugno Executive Chairman of Board |
BUY
Open market or private purchase
|
Direct |
4,000
+19.5%
|
$12,000
$3.53 P/Share
|
|
Apr 08
2022
|
Frederick J. Fritz Director |
BUY
Open market or private purchase
|
Direct |
5,000
+29.82%
|
$20,000
$4.05 P/Share
|
|
Mar 02
2022
|
Frederick J. Fritz Director |
BUY
Open market or private purchase
|
Direct |
2,000
+22.82%
|
$8,000
$4.69 P/Share
|
|
Dec 14
2021
|
Constantine John Kardaras Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Oct 07
2021
|
Frederick J. Fritz Director |
BUY
Open market or private purchase
|
Direct |
20,000
+21.86%
|
$0
$0.88 P/Share
|
|
May 17
2021
|
Donald P Braun Director |
BUY
Open market or private purchase
|
Direct |
5,000
+48.28%
|
$5,000
$1.07 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 50K shares |
|---|---|
| Grant, award, or other acquisition | 20K shares |